A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
Status:
Recruiting
Trial end date:
2024-08-13
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of PM012 tablets for Alzheimer's disease, dose-finding
study will be performed on phase 2b, and the established dose will be used for the
non-inferiority phase 3 trial to evaluate the investigational product's safety and efficacy:
Double blind, randomized, active drug comparative, multi-center, parallel-group clinical
trial